"The treatment landscape for many of the more common cancers continues to expand thanks to the success of the combination of checkpoint inhibitors drugs such as Merck's anti – PD1 therapy Keytrudawith new drugs such as CAVATAK.
Loading...
Elise Shaw writes on Markets specialising in Equity Markets, Commodities, Mining. Based in our Sydney newsroom, Elise has over 25 years experience as a finance and markets journalist and editor. Connect with Elise on Twitter.
